Limits...
Water-soluble L-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma.

Liang S, Zhou Q, Wang M, Zhu Y, Wu Q, Yang X - Int J Nanomedicine (2015)

Bottom Line: The MRI and CT imaging ability of FePt-Cys NPs was evaluated using different gliomas cells (C6, SGH44, U251) as the model.Furthermore, the biocompatibility of the as-synthesized FePt-Cys NPs was evaluated using three different cell lines (ECV304, L929, and HEK293) as the model.The results showed that FePt-Cys NPs displayed excellent biocompatibility and good MRI/CT imaging ability, thereby indicating promising potential as a dual MRI/CT contrast agent for the diagnosis of brain malignant gliomas.

View Article: PubMed Central - PubMed

Affiliation: College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

ABSTRACT
Nanoparticles (NPs) are advantageous for the delivery of diagnosis agents to brain tumors. In this study, we attempted to develop an L-cysteine coated FePt (FePt-Cys) NP as MRI/CT imaging contrast agent for the diagnosis of malignant gliomas. FePt-Cys NPs were synthesized through a co-reduction route, which was characterized by transmission electron microscopy, high-resolution transmission electron microscopy, powder X-ray diffraction, Fourier transform infrared spectroscopy, and dynamic light scattering. The MRI and CT imaging ability of FePt-Cys NPs was evaluated using different gliomas cells (C6, SGH44, U251) as the model. Furthermore, the biocompatibility of the as-synthesized FePt-Cys NPs was evaluated using three different cell lines (ECV304, L929, and HEK293) as the model. The results showed that FePt-Cys NPs displayed excellent biocompatibility and good MRI/CT imaging ability, thereby indicating promising potential as a dual MRI/CT contrast agent for the diagnosis of brain malignant gliomas.

No MeSH data available.


Related in: MedlinePlus

Imaging of different gliomas cells (C6, SGH44, and U251) treated with FePt-Cys NPs.Notes: (A) MR imaging of different gliomas cells at different Fe concentrations; (B) CT imaging of different gliomas cells at different Pt concentrations.Abbreviations: CT, computed tomography; FePt-Cys, l-cysteine coated FePt; MR, magnetic resonance; NPs, nanoparticles.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4376264&req=5

f8-ijn-10-2325: Imaging of different gliomas cells (C6, SGH44, and U251) treated with FePt-Cys NPs.Notes: (A) MR imaging of different gliomas cells at different Fe concentrations; (B) CT imaging of different gliomas cells at different Pt concentrations.Abbreviations: CT, computed tomography; FePt-Cys, l-cysteine coated FePt; MR, magnetic resonance; NPs, nanoparticles.

Mentions: The MR imaging of FePt-Cys NPs was further evaluated using different glioma cells (C6, SGH44, and U251), as shown in Figure 8A. When FePt-Cys NPs were incubated with C6 glioma cells at different Fe concentrations, a gradual MR signal decay was observed with increasing of the Fe concentration from 0 μg/mL to 20 μg/mL. The Fe concentration-dependent MR signal decay was also observed on SGH44 cells and U251 cells. The CT imaging of FePt-Cys NPs was evaluated using three glioma cells (C6, SGH44, and U251) at different Pt concentrations. As shown in Figure 8B, a significant enhancement of the gray-scale signal can be observed with increasing Pt concentration on three glioma cells. These results suggested that FePt-Cys NPs could be used as MR and CT contrast agents in glioma cells.


Water-soluble L-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for glioma.

Liang S, Zhou Q, Wang M, Zhu Y, Wu Q, Yang X - Int J Nanomedicine (2015)

Imaging of different gliomas cells (C6, SGH44, and U251) treated with FePt-Cys NPs.Notes: (A) MR imaging of different gliomas cells at different Fe concentrations; (B) CT imaging of different gliomas cells at different Pt concentrations.Abbreviations: CT, computed tomography; FePt-Cys, l-cysteine coated FePt; MR, magnetic resonance; NPs, nanoparticles.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4376264&req=5

f8-ijn-10-2325: Imaging of different gliomas cells (C6, SGH44, and U251) treated with FePt-Cys NPs.Notes: (A) MR imaging of different gliomas cells at different Fe concentrations; (B) CT imaging of different gliomas cells at different Pt concentrations.Abbreviations: CT, computed tomography; FePt-Cys, l-cysteine coated FePt; MR, magnetic resonance; NPs, nanoparticles.
Mentions: The MR imaging of FePt-Cys NPs was further evaluated using different glioma cells (C6, SGH44, and U251), as shown in Figure 8A. When FePt-Cys NPs were incubated with C6 glioma cells at different Fe concentrations, a gradual MR signal decay was observed with increasing of the Fe concentration from 0 μg/mL to 20 μg/mL. The Fe concentration-dependent MR signal decay was also observed on SGH44 cells and U251 cells. The CT imaging of FePt-Cys NPs was evaluated using three glioma cells (C6, SGH44, and U251) at different Pt concentrations. As shown in Figure 8B, a significant enhancement of the gray-scale signal can be observed with increasing Pt concentration on three glioma cells. These results suggested that FePt-Cys NPs could be used as MR and CT contrast agents in glioma cells.

Bottom Line: The MRI and CT imaging ability of FePt-Cys NPs was evaluated using different gliomas cells (C6, SGH44, U251) as the model.Furthermore, the biocompatibility of the as-synthesized FePt-Cys NPs was evaluated using three different cell lines (ECV304, L929, and HEK293) as the model.The results showed that FePt-Cys NPs displayed excellent biocompatibility and good MRI/CT imaging ability, thereby indicating promising potential as a dual MRI/CT contrast agent for the diagnosis of brain malignant gliomas.

View Article: PubMed Central - PubMed

Affiliation: College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, People's Republic of China.

ABSTRACT
Nanoparticles (NPs) are advantageous for the delivery of diagnosis agents to brain tumors. In this study, we attempted to develop an L-cysteine coated FePt (FePt-Cys) NP as MRI/CT imaging contrast agent for the diagnosis of malignant gliomas. FePt-Cys NPs were synthesized through a co-reduction route, which was characterized by transmission electron microscopy, high-resolution transmission electron microscopy, powder X-ray diffraction, Fourier transform infrared spectroscopy, and dynamic light scattering. The MRI and CT imaging ability of FePt-Cys NPs was evaluated using different gliomas cells (C6, SGH44, U251) as the model. Furthermore, the biocompatibility of the as-synthesized FePt-Cys NPs was evaluated using three different cell lines (ECV304, L929, and HEK293) as the model. The results showed that FePt-Cys NPs displayed excellent biocompatibility and good MRI/CT imaging ability, thereby indicating promising potential as a dual MRI/CT contrast agent for the diagnosis of brain malignant gliomas.

No MeSH data available.


Related in: MedlinePlus